Best Diffuse Large B Cell Lymphoma Podcasts (2025)

1
GATA Lot to Learn: Decoding the Drivers of Down Syndrome-Associated Acute Leukemias 21:13

Play Pause

4d ago21:13

21:13

In this episode, Contributing Editor, Lauren Pommert, MD, MS, leads a conversation with Karen Rabin, MD, PhD, pediatric oncologist at the University of California, San Francisco, and Hans Hitzler, MD, with SickKids Children's Hospital in Toronto. They discuss advances in understanding the disease biology of down syndrome associated acute leukemia. …

1
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas 29:59

5d ago29:59

29:59

In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including: The clinical implications of using DLL3 as a therapeutic target The impact of emerging DLL3-targeted therapies on evolving treatment paradigms How to incorpor…

1
Highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting — Driving Knowledge to Action: Building a Better Future 1:30:31

8d ago1:30:31

1:30:31

- Treatment Updates from ASCO 2025 on Lung Cancer- Supportive Care Issues- Treatment Updates from ASCO 2025 on Colorectal Cancer- Quality-of-Life Concerns- Update on Pancreas Cancer- Supportive Care Concerns- Update on Lymphoma- Communicating with Your Health Care Team- Updates on Leukemia from ASCO- Managing Treatment Side Effects- Updates on Mela…

1
Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective 24:49

8d ago24:49

24:49

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including: Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules Avail…

1
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025 39:12

23d ago39:12

39:12

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings. Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL ECHO: Rituximab-Bendamustine ±…

1
More Than Medicine: Peer Connection as a Therapeutic Adjunct in Acute Leukemia 22:54

24d ago22:54

22:54

In this episode, Contributing Editor Lori Muffly, MD, MS, leads a conversation with two patients — Matt and Rohan — both of whom have undergone cord blood transplants for their acute myeloid leukemia. They discuss the value of peer connection as a vital component of their leukemia and transplant journey.…

1
Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting 35:02

26d ago35:02

35:02

In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic brea…

1
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC 18:04

26d ago18:04

18:04

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC: Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs…

1
A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors? 22:23

27d ago22:23

22:23

In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care. Presenters: Eytan M. Stein, MD Chief, Leukemia Service Director, Program for Drug Development in Leukemia Associate Attending P…

1
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025 21:24

29d ago21:24

21:24

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including: The randomized phase III FLAIR trial The randomized phase III SEQUOIA trial The randomized phase III BRUIN CLL-321 trial Pres…

1
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma 31:19

1M ago31:19

31:19

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including: Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC Overview of the Latest Data for the Combination of …

1
Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies 35:36

1M ago35:36

35:36

In this episode, Jonathan W. Friedberg, MD; Alex F. Herrera, MD; and Kara Kelly, MD, discuss the latest frontline treatment options for advanced Hodgkin lymphoma (HL) and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients. This podcast was adapted from a live presentation held in May 202…

1
Experts Discuss CELMoDs in Myeloma 35:51

1M ago35:51

35:51

In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: Mechanistic differences between CELMoDs and IMiDs Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma The clinical implicatio…

1
Treating Metastatic HER2-negative Breast Cancer: Oncology Nursing Approaches to Improve Patient Quality of Life 49:37

1M ago49:37

49:37

In this enduring CEC ONS Chapter installment, expert faculty will review emerging data on ADC use for HER2-neg MBC and share insights and strategies on the impact of AEs associated with ADC use and approaches to the management of AEs associated with ADCs in this patient population. To learn more: https://www.ceconcepts.com/activity/treating-metasta…

1
Advancing Cervical Cancer Care: Navigating New Therapies, Guidelines, and Patient-Centric Approaches 48:09

2M ago48:09

48:09

In this CE Concepts Grand Rounds series, expert faculty will examine the evolving treatment landscape for advanced cervical cancer and discuss how they develop individualized treatment plans that apply current guideline recommendations, consider new treatment methods, and respect the unique needs of each patient. Find more details and collect credi…

1
Addressing the LGBTQI+ Health Disparities Gap 56:55

2M ago56:55

56:55

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV- The LGBTQI+ Community’s Disproportionate Cancer Burden- Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers- Barriers to Health Care Access, Including Discrimination- Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housi…

1
Addressing the LGBTQI+ Health Disparities Gap 56:55

2M ago56:55

56:55

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV- The LGBTQI+ Community’s Disproportionate Cancer Burden- Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers- Barriers to Health Care Access, Including Discrimination- Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housi…

1
Children as Caregivers for a Loved One with Cancer 56:06

2M ago56:06

56:06

- Definition of a Caregiver- What Research Tells Us About Children as Caregivers’ Well Being- Children as Caregivers- Children as Caregivers for a Sibling- Children as Caregivers for a Parent- Children as Caregivers for a Grandparent- Children as Caregivers for an Older Adult- Children as Caregivers for a Younger Adult- Children as Caregivers for C…

1
Children as Caregivers for a Loved One with Cancer 56:06

2M ago56:06

56:06

- Definition of a Caregiver- What Research Tells Us About Children as Caregivers’ Well Being- Children as Caregivers- Children as Caregivers for a Sibling- Children as Caregivers for a Parent- Children as Caregivers for a Grandparent- Children as Caregivers for an Older Adult- Children as Caregivers for a Younger Adult- Children as Caregivers for C…

1
Pomalidomide: A Step on the PATH Forward for Treatment of Hereditary Hemorrhagic Telangiectasia 22:00

2M ago22:00

22:00

In this episode, Contributing Editor Surbhi Shah, MBBS, MD, a clinician, researcher, and educator at Mayo Clinic in Phoenix, Arizona, talks with Keith McCrae, MD, director of classical hematology at the Taussig Cancer Institute and professor of molecular medicine at the Cleveland Clinic Lerner College of Medicine in Ohio. They discuss a recent pape…

1
MEK Inhibitors in Neurofibromatosis Type 1: Latest Advances and Real-World Applications in NF1-PN Management 1:03:44

2M ago1:03:44

1:03:44

In this CEC Oncology recorded, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person’s lifespan; explore the integration of MEK inhibitors in the management of NF1-associated PNs in pediatric patients; and consider comprehensive interprofessional care plans that include disease monitoring, toxicity managem…

1
Diverse Populations Participating in Decisions About Your Care with Your Health Care Team 1:03:12

2M ago1:03:12

1:03:12

- How Being a Member of Diverse Communities May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects, & Pain Management- What to Expect from Your Relationship with Your Health Care Team: Is Your Health Care Team Providing You with Equitable, Excellent Care- What to Consider When Selecting a Cancer Care Team & Treatme…

1
Diverse Populations Participating in Decisions About Your Care with Your Health Care Team 1:03:12

2M ago1:03:12

1:03:12

- How Being a Member of Diverse Communities May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects, & Pain Management- What to Expect from Your Relationship with Your Health Care Team: Is Your Health Care Team Providing You with Equitable, Excellent Care- What to Consider When Selecting a Cancer Care Team & Treatme…

1
Current Perspectives on the Future of Cancer Research 1:05:29

3M ago1:05:29

1:05:29

- Understanding the Future of Cancer Research & Clinical Trials- Increased Focus on Earlier Detection & Treatment of Cancer- Health Care Disparities Research- Enhanced Knowledge of the Molecular Portrait of Cancer- Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer- Microsatellite Instability (MSI): Mutations in DNA …

1
Current Perspectives on the Future of Cancer Research 1:05:29

3M ago1:05:29

1:05:29

- Understanding the Future of Cancer Research & Clinical Trials- Increased Focus on Earlier Detection & Treatment of Cancer- Health Care Disparities Research- Enhanced Knowledge of the Molecular Portrait of Cancer- Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer- Microsatellite Instability (MSI): Mutations in DNA …

1
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care 51:55

3M ago51:55

51:55

- Disproportionate Burden of Cancer & Infectious Diseases on People of Color- Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care- Influence of the Local & Regional Environment in Which You Live- How Race May Impact Your Access to Oncology Care, Tre…

1
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care 51:55

3M ago51:55

51:55

- Disproportionate Burden of Cancer & Infectious Diseases on People of Color- Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care- Influence of the Local & Regional Environment in Which You Live- How Race May Impact Your Access to Oncology Care, Tre…

1
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities 35:15

3M ago35:15

35:15

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including: Key Comorbidit…

1
Dual BCR::ABL1 Inhibition Shows Promise in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 18:31

3M ago18:31

18:31

In this episode, Contributing Editor Scott Furlan, MD, PhD, an assistant professor at the Fred Hutch Cancer Center and Department of Pediatrics at the University of Washington in Seattle, talks with Daniel J. DeAngelo, MD, PhD, chief of the leukemia division at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School i…

1
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications 21:54

3M ago21:54

21:54

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and…

1
When to STOP Treatment for Immune Thrombocytopenia in Patients Experiencing a Complete Response on Thrombopoietin Receptor Agonists 10:34

3M ago10:34

10:34

In this episode, Contributing Editor Michael Scott, MD, a hematologist at St. Michael’s Hospital in Toronto, Canada, and an assistant professor at the University of Toronto, talks with Marc Michel, MD, MSc, head of the internal medicine and clinical immunology department at Henri Mondor University Hospital in Créteil, France. They talk about long-t…

1
Update on Follicular Lymphoma 51:28

3M ago51:28

51:28

- Overview of Follicular Lymphoma- Treatment Options for Newly Diagnosed- Treatment Options for Relapsed/Refractory Disease- Clinical Trial Updates: How Research Increases Treatment Options- New & Emerging Treatments- Factors that May Affect Treatment Planning- Side Effect Prevention & Management- Tips to Improve Communicating with the Health Care …

1
Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates 1:00:44

4M ago1:00:44

1:00:44

- Overview of Diffuse Large B-Cell Lymphoma- Staging & Grading- Current Standard of Care- Treatment Options for Resistant Disease- New & Emerging Treatment Approaches- The Role of Clinical Trials- How Research Contributes to Treatment Choices- Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain- The Increasing Role of Telehealth/Tele…

1
Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates 1:00:44

4M ago1:00:44

1:00:44

- Overview of Diffuse Large B-Cell Lymphoma- Staging & Grading- Current Standard of Care- Treatment Options for Resistant Disease- New & Emerging Treatment Approaches- The Role of Clinical Trials- How Research Contributes to Treatment Choices- Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain- The Increasing Role of Telehealth/Tele…

1
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies 29:36

4M ago29:36

29:36

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers. Mechanisms of action of ADCs: how ADCs selective…

1
Cancer & the Workplace: Understanding Your Legal Protections 56:39

4M ago56:39

56:39

- The Meaning of Work- Talking with Your Health Care Team About Work- Managing Your Cancer Treatments While Working- Understanding Your Legal Protections in the Workplace, Including Americans with Disabilities Act (ADA)- Family Medical Leave Act (FMLA) & Intermittent FMLA- Equal Employment Opportunity Commission (EEOC) State & Local Laws- Disclosur…

1
Cancer & the Workplace: Understanding Your Legal Protections 56:39

4M ago56:39

56:39

- The Meaning of Work- Talking with Your Health Care Team About Work- Managing Your Cancer Treatments While Working- Understanding Your Legal Protections in the Workplace, Including Americans with Disabilities Act (ADA)- Family Medical Leave Act (FMLA) & Intermittent FMLA- Equal Employment Opportunity Commission (EEOC) State & Local Laws- Disclosur…

1
No Scientific Link Found Between Sickle Cell Trait and Sudden Death 21:07

4M ago21:07

21:07

In this episode, Contributing Editor Samuel Wilson, MD, MSCR, an assistant professor of hematology at the University of North Carolina at Chapel Hill, talks with Michael DeBaun, MD, MPH, a professor of pediatrics and medicine at Vanderbilt University Medical Center and founder and director of the Vanderbilt-Meharry Sickle Cell Disease Center of Exc…

1
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer 18:34

4M ago18:34

18:34

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3 Overview of the structure of antibody-drug conjugates (ADCs) Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-…

1
Understanding the Cost of Care & Your Health Care Coverage 1:00:33

4M ago1:00:33

1:00:33

- Overview of the Medical & Indirect Costs of Treatment- What to Do When Cancer Treatment Seems Unaffordable – Self Advocacy- Talking with Your Health Care Team about Your Financial Concerns- The Benefits & Limitations of Your Health Plans, Insurance, Medicare & Medicaid Coverage- Tips on Appealing Your Insurance & Medicare Claims & Provider Denial…

1
Understanding the Cost of Care & Your Health Care Coverage 1:00:33

4M ago1:00:33

1:00:33

- Overview of the Medical & Indirect Costs of Treatment- What to Do When Cancer Treatment Seems Unaffordable – Self Advocacy- Talking with Your Health Care Team about Your Financial Concerns- The Benefits & Limitations of Your Health Plans, Insurance, Medicare & Medicaid Coverage- Tips on Appealing Your Insurance & Medicare Claims & Provider Denial…

1
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies 14:09

4M ago14:09

14:09

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how …

1
Managing Eye and Vision Changes Related to Cancer Treatments 57:10

4M ago57:10

57:10

- Overview of Common Eye & Vision Changes Related to Cancer Treatments- Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors- Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights- The Role of the Multidisciplinary Team- Tips to Manage Low V…

1
Managing Eye and Vision Changes Related to Cancer Treatments 57:10

4M ago57:10

57:10

- Overview of Common Eye & Vision Changes Related to Cancer Treatments- Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors- Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights- The Role of the Multidisciplinary Team- Tips to Manage Low V…

1
Trends in Oncology & Treatment Planning: A Guide to Getting the Best Care 56:59

4M ago56:59

56:59

- Understanding Your Cancer Diagnosis & Treatment Options- Clinical Trial Opportunities: How Research Increases Treatment Options- Factors That May Affect Treatment Planning- How Your Health Care Team May Help You Address Your Care- Participating in Decisions about Your Treatment Plans, Side Effect Prevention & Management- Understanding the Role of…

1
Trends in Oncology & Treatment Planning: A Guide to Getting the Best Care 56:59

4M ago56:59

56:59

- Understanding Your Cancer Diagnosis & Treatment Options- Clinical Trial Opportunities: How Research Increases Treatment Options- Factors That May Affect Treatment Planning- How Your Health Care Team May Help You Address Your Care- Participating in Decisions about Your Treatment Plans, Side Effect Prevention & Management- Understanding the Role of…

1
Does This Star ‘GLO’? Taking Aim at Second-Line Diffuse Large B-Cell Lymphoma With Glofitamab Plus Gemcitabine and Oxaliplatin 20:16

5M ago20:16

20:16

In this episode, Contributing Editor Tycel Phillips, MD, an associate professor of medicine and a hematologist-oncologist at City of Hope Medical Center in Duarte, California, talks with Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital and an associate professor of medicine at Harvard …

1
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC 14:42

5M ago14:42

14:42

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including: Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastu…

1
Updates on CAR T-cell Therapies 53:09

5M ago53:09

53:09

- Overview of CAR T-Cell Therapies- Understanding CARs – Chimeric Antigen Receptors- When to Consider CAR T-Cell Therapies as a Treatment Choice- Clinical Trials for CAR T-Cell Therapies- Discussion of CAR T-Cell Therapies- Managing Potential Treatment Side Effects- Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care- Key Ques…

1
Updates on CAR T-cell Therapies 53:09

5M ago53:09

53:09

- Overview of CAR T-Cell Therapies- Understanding CARs – Chimeric Antigen Receptors- When to Consider CAR T-Cell Therapies as a Treatment Choice- Clinical Trials for CAR T-Cell Therapies- Discussion of CAR T-Cell Therapies- Managing Potential Treatment Side Effects- Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care- Key Ques…